A6178
5-氨基水杨酸
tablet
别名:
5-AS, 5-氨基-2-羟基苯甲酸, 氨水杨酸
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
H2NC6H3-2-(OH)CO2H
化学文摘社编号:
分子量:
153.14
EC Number:
201-919-1
UNSPSC Code:
12352204
PubChem Substance ID:
Beilstein/REAXYS Number:
2090421
MDL number:
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
SMILES string
Nc1ccc(O)c(c1)C(O)=O
form
tablet
mp
275-280 °C (dec.) (lit.)
storage temp.
2-8°C
Gene Information
human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
Application
5-氨基水杨酸是适用于ELISA分析的过氧化物酶底物。这一底物产生可溶性的棕色终产物，可在450nm处通过分光光度法读取。使用3 N NaOH可终止反应并在550 nm处读取结果。
Preparation Note
Contains 100 mg substrate per tablet.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
存储类别
13 - Non Combustible Solids
wgk
WGK 2
flash_point_f
No data available
flash_point_c
No data available
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
B Flourié et al.
Alimentary pharmacology & therapeutics, 37(8), 767-775 (2013-03-05)
Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. To compare the efficacy and safety of once- (OD) vs. twice- (BD) daily prolonged-release mesalazine (Pentasa, Ferring, Saint-Prex, Switzerland) for active mild-to-moderate UC in a
A Lyakhovich et al.
Alimentary pharmacology & therapeutics, 31(2), 202-209 (2009-11-07)
Mesalazine (mesalamine) (5-ASA) is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis. Besides its anti-inflammatory properties, 5-ASA has been studied for cancer
Alexander C Ford et al.
The American journal of gastroenterology, 106(12), 2070-2077 (2011-09-07)
Maintenance therapy with 5-aminosalicylates (5-ASAs) is recommended in patients with quiescent ulcerative colitis (UC), but compliance rates are low. Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied
John K Marshall et al.
The Cochrane database of systematic reviews, (1)(1), CD004115-CD004115 (2010-01-22)
5-Aminosalicylates (5-ASA) are considered a first-line therapy for inducing and maintaining remission of mild to moderately active ulcerative colitis (UC). When inflammation in UC is limited to the distal colon, 5-ASA can also be administered rectally as a suppository, enema
Urpo Nieminen et al.
International journal of cancer, 134(1), 189-196 (2013-06-26)
Patients with long-standing inflammatory bowel disease (IBD) have an increased risk for colorectal carcinoma (CRC). Earlier studies suggest that the severity of inflammation is an independent risk factor for CRC in ulcerative colitis (UC). We investigated the role of histological
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持